Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
176. |
ECCT/23/12/01 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL) |
Principal Investigator(s) 1. Prof Walter Jaoko 2. Dr. Lucas Thina Otieno 3. Prof. Kariuki Simon 4. Dr. Janet Nyawira Oyieko 5. Walter Otieno 6. Onono Dr. Marcianah 7. Dr. Lucas Thina Otieno 8. Prof. Kariuki Simon 9. Dr. Janet Nyawira Oyieko 10. Walter Otieno 11. Onono Dr. Marcianah Site(s) in Kenya 1. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. Walter Reed Army Institute of Research -Kericho Site (Kericho county) 4. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) 5. Siaya County Referral Hospital (SCRH (Siaya county) 6. Kenya Medical Research Institute Center for Microbiology Research (CMR (Kisumu county) 7. Kombewa Clinical Research Center, KEMRI, (Kisumu county) |
View |
177. |
ECCT/24/06/03 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr Walter Otieno Site(s) in Kenya 1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county) |
View |
178. |
ECCT/24/02/06 | INAVO122 A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
179. |
ECCT/22/01/04 | SKYSCRAPER 07 A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA WHOSE CANCERS HAVE NOT PROGRESSED FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY |
Principal Investigator(s) 1. Fredrick Chite Asirwa 2. Mansoor Saleh Site(s) in Kenya 1. Aga Khan University, Nairobi (Nairobi City county) 2. International Cancer Institute (Uasin Gishu county) |
View |
180. |
ECCT/23/11/05 | Alma Study Feasibility clinical study of the Alma system in treating Primary Postpartum Hemorrhage - Alma Study |
Principal Investigator(s) 1. Omondi Ogutu Site(s) in Kenya Kenyatta National Hospital |
View |